1. Who owned the other 51% of BMG? Per the SEC’s Correspondence on the S-1 disclosure, why was Globus so opposed to disclosing the "third-part vendor’s name" and what "harm" did it suppose would come to it and its owners?

From and after the filing of Globus Medical’s S-1, BMG had approximately a dozen stockholders. The related party transaction disclosure rules required that we disclose the interests of our executive management in BMG, which was 49% on an outstanding share basis and closer to 47% when you include the dilutive impact of BMG’s outstanding stock options. The remaining shares of BMG were owned by a number of other private investors.

At the time of Globus Medical’s IPO, BMG’s sales efforts were directed towards Globus and other medical device companies, including those that were competitors of Globus Medical. BMG felt that being linked to Globus Medical in its S-1 could harm its sales efforts. BMG asked us to keep their name out of our SEC filings if possible for this reason.

2. Who was the $2 million December 2009 investor? Was it Mahboob Khan?

Mr. Khan was an investor in BMG but did not provide the $2 million in equity financing obtained by BMG in 2009. Those funds were invested by another private individual.